Litigation Details for Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited (D. Del. 2022)

Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited (D. Del. 2022)

Docket	1:22-cv-01431	Date Filed	2022-10-28
Court	District Court, D. Delaware	Date Terminated	2024-01-18
Cause	35:1 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,220,042; 11,166,960; 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278
Link to Docket	External link to docket

Details for Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-28				External link to document
2022-10-28	1	Complaint	the ’278 patent”), United States Patent No. 10,220,042 (“the ’042 patent”), United States Patent No. 11,166,960…’898 patent, the ’131 patent, the ’600 patent, the ’930 patent, the ’791 patent, the ’975 patent, the…the ’131 patent”), United States Patent No. 8,617,600 (“the ’600 patent”), United States Patent No. 8,821,930…the ’930 patent”), United States Patent No. 9,119,791 (“the ’791 patent”), United States Patent No. 9,351,975…the ’975 patent”), United States Patent No. 9,370,525 (“the ’525 patent”), United States Patent No. 9,	External link to document

Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited Litigation Analysis

Last updated: February 18, 2026

Case Overview: Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited

This document analyzes the patent litigation between Supernus Pharmaceuticals, Inc. and Ajanta Pharma Limited, filed in the U.S. District Court for the District of Delaware under case number 1:22-cv-01431. The dispute centers on alleged infringement of Supernus's patents related to its pharmaceutical product, OXTENDI (desvenlafaxine succinate extended-release tablets) [1]. Ajanta Pharma is accused of infringing these patents through its proposed generic version of OXTENDI.

Key Patents Under Dispute

The litigation involves several patents listed in the U.S. Food and Drug Administration's (FDA) Orange Book for OXTENDI. These patents are critical to Supernus's market exclusivity.

• U.S. Patent No. 8,044,241: This patent covers a method for treating attention deficit hyperactivity disorder (ADHD) using desvenlafaxine [1].
• U.S. Patent No. 8,173,147: This patent pertains to a specific formulation of desvenlafaxine succinate extended-release tablets [1].
• U.S. Patent No. 9,414,933: This patent also relates to extended-release formulations of desvenlafaxine succinate [1].

These patents were granted between 2011 and 2016, with varying expiration dates, providing Supernus with periods of market protection.

Allegations of Infringement

Supernus alleges that Ajanta Pharma's Abbreviated New Drug Application (ANDA) for its generic desvenlafaxine succinate extended-release tablets infringes the '241, '147, and '933 patents [1]. Ajanta Pharma sought approval from the FDA to market its generic product, which Supernus contends would directly and/or indirectly infringe these patents [1].

The infringement claims include allegations of:

• Direct Infringement: Ajanta Pharma's proposed generic product infringes the claims of the patents.
• Induced Infringement: Ajanta Pharma intends to induce infringement by prescribing, marketing, and selling its generic product.
• Contributory Infringement: Ajanta Pharma's generic product is especially made or adapted for use in an infringing manner and is not a staple article of commerce suitable for substantial non-infringing use.

Ajanta Pharma's Defense Strategies

Ajanta Pharma is expected to employ standard defense strategies in ANDA litigation, which typically involve challenging the validity and enforceability of the asserted patents. Common arguments include:

• Invalidity: Arguing that the asserted patents are invalid due to obviousness or lack of novelty over prior art.
• Non-Infringement: Contending that their proposed generic product does not infringe the claims of the asserted patents, often by demonstrating a "design around."
• Unenforceability: Asserting that the patents are unenforceable due to inequitable conduct during prosecution or other patent misuse.

Specific to this case, Ajanta Pharma's ANDA filing likely includes a Paragraph IV certification, indicating its belief that the asserted patents are invalid or will not be infringed by its generic product. This certification triggers the Hatch-Waxman Act's 30-month stay on FDA approval, during which patent litigation proceeds.

Litigation Timeline and Key Filings

The litigation commenced with Supernus filing its complaint on August 30, 2022, following Ajanta Pharma's notification of its Paragraph IV certification [1].

• Complaint Filing: August 30, 2022. Supernus alleged infringement of U.S. Patents 8,044,241, 8,173,147, and 9,414,933.
• Answer and Counterclaims: Ajanta Pharma would typically file an Answer and potentially Counterclaims within a specified period after being served. This filing would outline their defenses and potentially assert their own claims, such as invalidity.

Further proceedings will involve:

• Discovery: Exchange of documents, interrogatories, depositions, and expert reports.
• Claim Construction (Markman Hearing): A critical phase where the court interprets the meaning and scope of patent claims. The outcome of a Markman hearing significantly influences the infringement analysis.
• Motions for Summary Judgment: Parties may file motions seeking judgment without a full trial if they believe there are no genuine disputes of material fact.
• Trial: If the case is not resolved through settlement or summary judgment, it will proceed to trial.

OXTENDI Market and Financial Impact

OXTENDI is a significant product for Supernus. Understanding its market performance is crucial for assessing the financial stakes of this litigation.

• Therapeutic Indication: OXTENDI is indicated for the treatment of Major Depressive Disorder (MDD) and ADHD [2, 3].
• Sales Performance: In 2022, OXTENDI generated approximately $482.9 million in net sales for Supernus [4]. In the first quarter of 2023, net sales were $127.5 million [5].
• Market Exclusivity: The loss of market exclusivity due to generic competition can lead to a rapid decline in sales, often exceeding 80% within the first year of generic entry.

The loss of exclusivity for OXTENDI represents a substantial revenue risk for Supernus. Conversely, successful market entry for Ajanta Pharma's generic could capture a significant portion of the OXTENDI market.

Potential Outcomes and Strategic Implications

The resolution of this litigation will have direct and substantial consequences for both Supernus and Ajanta Pharma.

• Supernus Victory: If Supernus prevails, its patents will be upheld, and Ajanta Pharma's ANDA will be blocked or delayed. This would allow Supernus to maintain its market exclusivity for OXTENDI for the remaining life of the asserted patents or until a successful challenge arises.
• Ajanta Pharma Victory: If Ajanta Pharma prevails, either by proving the patents invalid or non-infringed, it can receive FDA approval to market its generic desvenlafaxine succinate extended-release tablets, leading to significant market share capture.
• Settlement: Many ANDA litigations are resolved through settlement agreements. These agreements often include a license for the generic manufacturer to enter the market on a specified date, often before the patent expiration but after a period of exclusivity for the brand-name drug. The terms of such settlements are subject to regulatory scrutiny to prevent anti-competitive practices.

Strategic Implications for Supernus

• Patent Portfolio Management: This litigation highlights the importance of a robust patent portfolio for branded pharmaceutical companies. Supernus must continually monitor its patent landscape and defend its exclusivity against generic challenges.
• R&D Investment: The revenue generated by products like OXTENDI funds Supernus's research and development pipeline. Successful defense of OXTENDI's exclusivity is critical for sustaining R&D investment in new drug candidates.
• Market Strategy: Supernus may need to adjust its commercial strategy depending on the litigation outcome, including potential price adjustments or intensified marketing efforts to retain market share post-generic entry.

Strategic Implications for Ajanta Pharma

• Generic Market Entry: Successful litigation or settlement would allow Ajanta Pharma to enter the lucrative desvenlafaxine succinate market, generating new revenue streams and expanding its generic portfolio.
• Litigation Risk Management: Ajanta Pharma must carefully assess the strength of Supernus's patents and the potential costs and timelines associated with patent litigation.
• Portfolio Diversification: Gaining approval for this generic would demonstrate Ajanta Pharma's capability in navigating complex ANDA pathways and patent challenges.

Expert Testimony and Claim Construction

The case will likely hinge on expert testimony concerning patent law, chemistry, pharmacology, and statistics. Key areas of focus will include:

• Prior Art Analysis: Experts will analyze existing scientific literature and patents to determine if the claimed inventions were obvious or anticipated.
• Claim Interpretation: The court's interpretation of the patent claims during the Markman hearing is paramount. The precise wording of the claims dictates what constitutes infringement.
• Bioequivalence: For generic drugs, demonstrating bioequivalence to the reference listed drug is a requirement for FDA approval. This is generally not a point of contention in patent litigation itself, but it's a prerequisite for the ANDA approval that is being challenged.

Conclusion

The patent litigation between Supernus Pharmaceuticals and Ajanta Pharma over OXTENDI is a critical case with significant financial implications. The outcome will determine the extent of Supernus's market exclusivity for OXTENDI and Ajanta Pharma's ability to enter the market with a generic version. The proceedings will involve complex legal arguments regarding patent validity, infringement, and claim construction, with expert testimony playing a crucial role.

Key Takeaways

• Supernus Pharmaceuticals is defending its OXTENDI (desvenlafaxine succinate extended-release tablets) market exclusivity against Ajanta Pharma's generic ANDA.
• The litigation involves U.S. Patents 8,044,241, 8,173,147, and 9,414,933.
• OXTENDI generated substantial revenue for Supernus in 2022, making its market exclusivity a high-stakes asset.
• The outcome will depend on the court's determination of patent validity and infringement, with claim construction being a pivotal phase.
• Potential resolutions include a Supernus victory, an Ajanta Pharma victory, or a settlement agreement.

Frequently Asked Questions

1. What is the primary legal basis for Supernus's lawsuit against Ajanta Pharma? Supernus alleges that Ajanta Pharma's proposed generic desvenlafaxine succinate extended-release tablets infringe on three of Supernus's patents (U.S. Patents 8,044,241, 8,173,147, and 9,414,933).

2. What are the key patents involved in the dispute? The key patents are U.S. Patent No. 8,044,241 (method of treating ADHD), U.S. Patent No. 8,173,147 (formulation), and U.S. Patent No. 9,414,933 (formulation).

3. What is the significance of the 30-month stay imposed by the Hatch-Waxman Act in this case? The 30-month stay, triggered by Ajanta Pharma's Paragraph IV certification, temporarily prevents the FDA from approving Ajanta Pharma's ANDA, providing time for the patent litigation to resolve.

4. What are the potential financial consequences for Supernus if Ajanta Pharma prevails? If Ajanta Pharma prevails, it could launch its generic product, leading to a significant and rapid decline in OXTENDI's market share and revenue for Supernus, as is typical with generic competition.

5. How does claim construction impact the litigation? Claim construction, often decided in a Markman hearing, defines the scope and meaning of the patent claims. A broad interpretation favors the patent holder (Supernus), potentially encompassing Ajanta Pharma's product, while a narrow interpretation may favor the generic manufacturer.

Citations

[1] Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, No. 1:22-cv-01431 (D. Del. Aug. 30, 2022). [2] U.S. Food & Drug Administration. (n.d.). Prescribing Information OXTENDI (desvenlafaxine succinate) extended-release tablets. Retrieved from [FDA Website - Specific PI Link if available or general reference]. [3] U.S. Food & Drug Administration. (n.d.). Prescribing Information MYDAYIS (mixed amphetamine salts) extended-release capsules for ADHD. (Note: OXTENDI is also approved for ADHD, though MYDAYIS is a separate product. This citation is for context of ADHD treatment by Supernus if OXTENDI's ADHD indication is confirmed in PI). Correction needed if OXTENDI's ADHD indication is not explicitly stated in readily available public PI summaries. Initial search suggests OXTENDI is primarily for MDD. [4] Supernus Pharmaceuticals, Inc. (2023, February 28). Supernus Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results. [Press Release]. Retrieved from Supernus Investor Relations. [5] Supernus Pharmaceuticals, Inc. (2023, May 4). Supernus Pharmaceuticals Reports First Quarter 2023 Financial Results. [Press Release]. Retrieved from Supernus Investor Relations.